# Celgene

> Celgene is a VC fund in Summit backing Biotechnology and Health Care. See 65 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Summit, United States
- Total investments: 65
- Last investment: Oct 2019
- Lead investor: 26%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/celgene
- X (Twitter): http://twitter.com/celgene
- Website: https://www.bms.com
- Facebook: https://www.facebook.com/Celgene/

Celgene is a VC fund in Summit focused on Biotechnology and Health Care. Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluatingcompounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

## Contacts

5 contacts available for Celgene. Shizune tracks 8 team members at Celgene. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/celgene?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 44 | 68% |
| Health Care | 31 | 48% |
| Therapeutics | 22 | 34% |
| Medical | 18 | 28% |
| Pharmaceutical | 11 | 17% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 23 | 35% |
| Series A | 14 | 22% |
| Series C | 7 | 11% |
| Funding Round | 7 | 11% |
| Series D | 5 | 8% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 39 | 60% |
| Canada | 2 | 3% |
| China | 1 | 2% |
| Israel | 1 | 2% |
| Germany | 1 | 2% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gerald Masoudi | Executive Vice President, General Counsel and Corporate Secretary | 0 | https://shizune.co/investors/profile/gerald-masoudi |
| Richard Barker | Member of the Board of Directors | 0 | https://shizune.co/investors/profile/richard-barker |
| Robert Hershberg | Executive Vice President, Head of Business Development and Global Alliances | 0 | https://shizune.co/investors/profile/robert-m-hershberg |
| Angus Grant | Corporate Vice President, Business Development | 0 | https://shizune.co/investors/profile/angus-grant |
| Keith Usiskin | Executive Director | 0 | https://shizune.co/investors/profile/keith-usiskin |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cyteir Therapeutics | Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly ownedlead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks. | $40.2M | Series B | Oct 15, 2019 |  |
| Anokion | Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can betranslated to virtually any protein in numerous clinical indications. | $40M | Series B | Sep 11, 2019 |  |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $75M |  | Sep 05, 2019 |  |
| Oncorus | Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promisingcancer research and to support cancer care in the developing world. | $79.5M | Series B | Aug 21, 2019 |  |
| Cleave Therapeutics | Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer. | $12M | Series C | Aug 06, 2019 |  |
| Aitia | GNS Healthcare is a big data analytics company that focuses on discovering what works in the healthcare industry and for whom. They focus on advancing and applying industrial-scale data analytics to empower key healthcare stakeholders to solve complex care, treatment, and cost challenges. It was founded in 2000 and headquartered in Cambridge,Massachusetts. | $23M | Series D | Jul 09, 2019 |  |
| Vividion Therapeutics | Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery. Making accessible the broad set of proteins expressed in human cells, the company’s platform was spun out of the labs of Vividion’s scientific founders, a teamof experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients. | $82M | Series B | Apr 30, 2019 |  |
| Arrakis Therapeutics | Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care. | $75M | Series B | Apr 18, 2019 |  |
| HiberCell | HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis. The company was founded in 2019 and is based in New York. | $60.8M | Series A | Feb 07, 2019 |  |
| Biond Biologics | Biond Biologics is a discovery and development company in the prosperous and evolving field of cancer immunotherapy and autoimmune disorders. Biond aims to translate high quality science into breakthrough therapies that will address unmet medical needs while focusing on innovative drugs. Biond is an Israeli company located at Galilee region,combining excellent science and out of the box innovation. | $17M | Series B | Jan 08, 2019 |  |

10 of 65 investments shown.

## Co-investors
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 8 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 7 deals together
- [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 5 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 5 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 5 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 5 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Celgene invest in?

Celgene invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 65 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Celgene?

Public channels for Celgene include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Celgene?

The team at Celgene includes Gerald Masoudi (Executive Vice President, General Counsel and Corporate Secretary), Richard Barker (Member of the Board of Directors) and Robert Hershberg (Executive Vice President, Head of Business Development and Global Alliances), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co